NCT02036645

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 55 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.

Conditions

• Mild-Moderate Alzheimer's Disease
• Healthy Elderly

Interventions

Type	Name	Description
BIOLOGICAL	MEDI1814 for IV injection	Monoclonal antibody for IV Injection
BIOLOGICAL	MEDI1814 for Subcutaneous Injection	Monoclonal antibody for subcutaneous injection
BIOLOGICAL	IV Placebo	Placebo for IV injection
BIOLOGICAL	Placebo for Subcutaneous Injection	Subcutaneous Placebo Injection

Timeline

• Start date: 2014-02-04
• Primary completion: 2016-09-15
• Completion: 2016-09-15
• First posted: 2014-01-15
• Last updated: 2019-06-03
• Results posted: 2019-06-03

Locations

10 sites across 1 country: United States